Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. 

Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group.

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. Abstract 


High prevalence of reduced bone mineral density in primary HIV-1-infected men. Grijsen ML, Vrouenraets SM, Steingrover R, Lips P, Reiss P, Wit FW, Prins JM.   

AIDS. 2010 Sep 10;24(14):2233-8. Abstract 


Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Bunnik EM, Euler Z, Welkers MR, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H.   

Nat Med. 2010 Sep;16(9):995-7. Epub 2010 Aug 29. Abstract 

Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange
Lancet. 2010 Jul 31;376(9738):340-5. Epub 2010 Jul 15.

Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners.
Hallett TB, Smit C, Garnett GP, de Wolf F.
Sex Transm Infect. 2010 Jul 18. [Epub ahead of print]

Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
Zhang S, van Sighem A, Gras L, Reiss P, Smit C, Kroon F, Jurriaans S, Prins J, Lange J, de Wolf F.
Antivir Ther. 2010;15(4):555-62.

Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.
van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F; ATHENA national observational cohort study.
AIDS. 2010 Jun 19;24(10):1527-35.

Late presentation of HIV infection: a consensus definition.
Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, Girardi E, Johnson M, Kirk O, Lundgren J, Mocroft A, d'Arminio Monforte A, Phillips A, Raben D, Rockstroh JK, Sabin C, Sönnerborg A, de Wolf F; for the European Late Presenter Consensus wo
HIV Med. 2010 Jun 17. [Epub ahead of print]

Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1 infected immigrants in the Netherlands
Kesselring AM, Gras L, Wit FW, Smit C, Geerlings SE, Mulder JW, Schreij G, Sprenger HG, Reiss P, de Wolf F
Antivir Ther. 2010;15(6):871-9.

27 years of the HIV epidemic amongst men having sex with men in the Netherlands: An in depth mathematical model-based analysis.
Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Fraser C
Epidemics. 2010 June; 2(2):66-70

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.
Antiretroviral Therapy Cohort Collaboration.
Clin Infect Dis. 2010 May 15;50(10):1387-96.

Measuring the Quality of Data Collection in a Large Observational Cohort of HIV and AIDS
Hillebregt M, De Lange-de Klerk E, Knol D, De Wolf F, Smit C
Open AIDS J. 2010;4:96-102. Epub 2010 May

Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection.
Steingrover R, Garcia EF, van Valkengoed IG, Bekker V, Bezemer D, Kroon FP, Dekker L, Prins M, de Wolf F, Lange JM, Prins JM.
AIDS Res Hum Retroviruses. 2010 Apr;26(4):379-87

Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings.
Revell AD, Wang D, Harrigan R, Hamers RL, Wensing AM, Dewolf F, Nelson M, Geretti AM, Larder BA.
J Antimicrob Chemother. 2010 Apr;65(4):605-7. Epub 2010 Feb 12.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, García F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warsawski J, Thorne C, Masip J, Pérez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Günthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chêne G, Lundgren JD, Phillips AN.
Arch Intern Med. 2010 Mar 8;170(5):410-9.

Superinfection with a heterologous HIV strain per se does not lead to faster progression.
Fung IC, Gambhir M, van Sighem A, de Wolf F, Garnett GP.
Math Biosci. 2010 Mar;224(1):1-9. Epub 2009 Nov 20.

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.
Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group.
AIDS. 2010 Jan 28;24(3):427-35

Transmission networks of resistant HIV-1 among men who have sex with men in the Netherlands
Bezemer D, van Sighem A, v. Lukashov V, van der Hoek L, Back N, Schuurman R, Boucher C, Claas E, Boerlijst MC, Coutinho R, de Wolf F for the ATHENA observational cohort
AIDS. 2010 Jan 16;24(2):271-82

Health-related quality of life independently predicts survival among HIV infected patients on HAART in the ATHENA-cohort.
De Boer-van der Kolk IM, Sprangers MAG, Smit C, de Wolf F, Prins JM, Nieuwkerk PT
Clin Infect Dis. 2010 Jan 15;50(2):255-63

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
The HIV-Causal Collaboration
AIDS. 2010 Jan 2;24(1):123-37


A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy
Wang D, Larder B, Revell A, Montaner J, Harrigan R, de Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, D'Arminio Monforte A, Torti C, Zazzi M, Lane C
Artif Intell Med. 2009 September;47(1):63-74

Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study
van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna A, Beniowski M, Lundgren JD, Burger DM; EuroSIDA Study Group
Antivir Ther. 2009;14(1):75-83

Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir
Van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, de Wolf F, Reiss
HIV Clin Trials. 2009 May-June;10(3):168-80

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin
L'homme RF, Nijland HM, Gras L, Aarnoutse RE, van Crevel R, Boeree M, Brinkman K, Prins JM, Juttmann JR, Burger DM
AIDS. 2009 Apr 27;27(7):863-5

Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations
Van Luin M, Gras L, Richter C, Ende ME, Prins JM, Wolf FD, Burger DM, Wit FW
J Acquir Immune Defic Syndr. 2009 July 10 52:240–245

Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression
Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Costagliola D, Elzi L, Mugavero MJ, D’Arminio Monforte A, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JAC; The Antiretroviral Therapy Cohort Collaboration
J Acquir Immune Defic Syndr. 2009 November 1 52(3):357-63

Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load
Baggaley RF, Griffin JT, Chapman R, Hollingsworth TD, Nagot N, Delany S, Mayaud P, de Wolf F, Fraser C, Ghani AC, Weiss HA
AIDS. 2009 May 15;23(8):1005-13

Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill F, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d’Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. The Antiretroviral Therapy Cohort Collaboration
International Journal of Epidemiology. October 2009

Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy
Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Murillo AMC, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Ludgren J, Egger M; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group
AIDS. 2009 September 24;23(15):2029-37

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements
Lanoy E, May M, Mocroft A, Phillips A, Justice A, Chêne G, Sterling T, D'Arminio Monforte A, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khyakin P, Sterne ACJ, Costagliola D; The antiretroviral therapy cohort collaboration (ART-CC)
AIDS. 2009 October 23;23(16):2199-2208

Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005
Sullivan PS, Hamouda O, Delpech V, Geduld JE, Prejean J, Semaille C, Kaldor J, Folch C, Op de Coul E, Marcus U, Hughes G, Archibald CP, Cazein F, McDonald A, Casabona J, van Sighem A, Fenton KA; Annecy MSM Epidemiology Study Group
Ann Epidemiol. 2009 June;19(6):423-31

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy
Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration
AIDS. 2009 August 24;23(13):1689-99

Sexually transmitted infections, including HIV, in the Netherlands in 2008  
Koedijk FDH, Vriend HJ, van Veen MG, Op de Coul ELM, van den Broek IVF, Van Sighem A, Verheij RA, van der Sande MAB. National Institute for Public health and the Environment, Bilthoven, 2009
RIVM reportnumber 210261005

Superinfection with a heterologous HIV strain per se does not lead to faster progression
Fung IC, Gambhir M, van Sighem A, de Wolf F, Garnett GP.
Math Biosci. 2009 Nov 20. [Epub ahead of print]

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal
When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR
Lancet. 2009 Apr 18;373(9672):1352-63. Epub 2009 Apr 8

Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands
Gras L, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Lange J, Prins JM, Berkhout B, de Wolf F, on behalf of the ATHENA national observational cohort study
PLoS One. 2009 October 7;4(10):e7365

Which method of adherence measurement is most suitable for daily use to predict virological failure among immigrant and non-immigrant HIV-1 infected patients?
Nellen JFJB, Nieuwkerk PT, Burger DM, Wibaut M, Gras L, Prins JM
AIDS Care July 2009 21 (7); 842 - 850


A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy
Bezemer, Daniela a; de Wolf, Frank a,b; Boerlijst, Maarten C c; van Sighem, Ard a; Hollingsworth, T Deirdre b; Prins, Maria d,e; Geskus, Ronald B d,f; Gras, Luuk a; Coutinho, Roel A g,h; Fraser, Christophe b
AIDS. 22(9):1071-1077, May 31, 2008
Link to publication

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction
Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD
Clin Infect Dis. 2008 Apr 1;46(7):1101-10
Link to publication

Combination antiretroviral therapy failure and HIV super-infection.
Bezemer D, van Sighem A, de Wolf F, Cornelissen M, van der Kuyl AC, Jurriaans S, van der Hoek L, Prins M, Coutinho RA, Lukashov VV.
HIV Monitoring Foundation, Academic Medical Centre, University of Amsterdam, the Netherlands.
AIDS. 2008 Jan 11;22(2):309-11
Link to publication

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.
Clin Infect Dis. 2008 Mar 15;46(6):933-40.
Link to publication

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski
AIDS. 2008 Nov 30;22(18):2481-92
Link to publication

Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART
Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, D'Arminio Monforte A, Lundgren JD; Eurosida Study Group
Scand J Infect Dis. 2008;40(11-12):908-13
Link to publication

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies
Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
AIDS. 2008 Oct 18;22(16):2143-53
Link to publication

Immunologic, Virologic, and Clinical Consequences of Episodes of Transient Viremia During Suppressive Combination Antiretroviral Therapy
van Sighem A, Zhang S, Reiss P, Gras L, van der Ende M, Kroon F, Prins J, de Wolf F; on Behalf of the ATHENA National Observational Cohort Study.
J Acquir Immune Defic Syndr.
Link to publication

Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands
Smit C, Hallett TB, Lange J, Garnett G, de Wolf F
PLoS One. 2008 Apr 9;3(4):e1949
Link to publication

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
Antiretroviral Therapy Cohort Collaboration
Lancet. 2008 Jul 26;372(9635):293-9
Link to publication

Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohort
de Boer-van der Kolk IM, Sprangers MA, van der Ende M, Schreij G, de Wolf F, Nieuwkerk PT
Acquir Immune Defic Syndr. 2008 Dec 1;49(4):460-2
Link to publication

Lymphogranuloma venereum proctitis in men who have sex with men is associated with anal enema use and high-risk behavior
de Vries HJ, van der Bij AK, Fennema JS, Smit C, de Wolf F, Prins M, Coutinho RA, Morré SA
Sex Transm Dis. 2008 Feb;35(2):203-8
Link to publication

Mortaliteit en morbiditeit in het HAART tijdperk
L. Gras
HIV Aids Nieuwsbulletin. Special CROI 2008.
Publication as attachment

Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies
Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M; Antiretroviral Therapy Cohort Collaboration
Antivir Ther. 2008;13(8):959-67
Link to publication

Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006
Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, Rodes B, Albert J, Böni J, Garson J, Ferns B, Matheron S, Chene G, Brun-Vezinet F; ACHIEV2E Collaboration on HIV-2 Infection Study Group
J Clin Microbiol. 2008 Jun;46(6):2088-91. Epub 2008 Apr 23
Link to publication

Response to combination antiretroviral therapy: variation by age
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group.
AIDS. 2008 Jul 31;22(12):1463-73
Link to publication

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study
Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):221-5
Link to publication

Sexually transmitted infections, including HIV, in the Netherlands in 2007
Broek IVF van den, Koedijk FDH, Veen MG van, Op de Coul ELM, Sighem AI van, Sande MAB van der
RIVM Rapport 210261004
Link to publication

Steady-state nevirapine plasma concentrations are influenced by pregnancy
Nellen JF, Damming M, Godfried MH, Boer K, van der Ende ME, Burger DM, de Wolf F, Wit FW, Prins JM Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS and Centre for Infection and Immunity Amsterdam, Academic Medi
HIV Med. 2008 Apr;9(4):234-8
Link to publication

Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33
Link to publication

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study GroupsAIDS. 2008 Sep 12;22(14):F17-24
Link to publication

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD.
Lancet. 2008 Apr 26;371(9622):1417-26. Epub 2008 Apr 2
Link to publication


25 years of HIV - Trends in Mortality, HIV coinfections, and HIV-related risk behaviour.
Thesis 2007, Colette Smit, Zaandam, the Netherlands.
Link to publication
Publication as attachment

ATHENA: uniek nationaal observationeel cohort van hiv-geïnfecteerde patiënten in Nederland
HIV/AIDS Nieuwsbulletin, jaargang 1, nummer 1, 10-11 (2007), F. de Wolf, ATHENA, Van Zuiden Communications. www.vanzuidencommunications.nl
Publication as attachment

CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.
Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, Miedema F, Reiss P, Lange JM, de Wolf F; ATHENA, Netherlands National Observational Cohort Study.HIV Monitoring Foundation, Amsterdam, The Netherlands.
J. Acquir Immune Defic Syndr. 2007 Jun 1;45(2):183-92.
Link to publication

Chronic renal failure among HIV-1-infected patients.
Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD.
AIDS. 2007 May 31;21(9):1119-27.
Link to publication

Class of antiretroviral drugs and the risk of myocardial infarction.
DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD.
N Engl J Med. 2007 Apr 26;356(17):1723-35.
Link to publication

Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
Pogány K, van Valkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, Kroon FP, Verbon A, Nievaard MF, Lange JM, Brinkman K.
J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):395-400.
Link to publication
Research page

Full participation in harm reduction programmes is associated with decreased risk for human immuno-deficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M; Amsterdam Cohort.
Addiction. 2007 Sep;102(9):1454-62.
Link to publication

Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients
Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L, Mocroft A, Phillips AN, Olsen CH, Gatell JM, Gunthard HF, Reiss P, Perno CF, Clotet B, Lundgren JD; EuroSIDA Study Group
J Infect Dis. 2007 Oct 15;196(8):1180-90. Epub 2007 Sep 19
Link to publication

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients.
Antiretroviral Therapy Cohort Collaboration.
J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):607-15.
Link to publication

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.
Van den Berg CH, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, Coutinho RA, Wolthers KC, Prins M.
Eur J Epidemiol. 2007;22(3):183-93. Epub 2007 Mar 3.
Link to publication

Monitoring of Human Immunodeficiency Virus (HIV) infection in the Netherlands Report 2007
Gras L, van Sighem A, Smit C, Zaheri S, Schuitemaker H and de Wolf F, on behalf of the Netherlands collaborative HIV treatment centres. HIV Monitoring Foundation, Amsterdam, the Netherlands.
Link to publication

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
The Antiretroviral Therapy (ART) Cohort Collaboration.
AIDS. 2007 May 31;21(9):1185-97.
Link to publication
Research page

Rise in seroprevalence of herpes simplex virus type 1 among highly sexual active homosexual men and an increasing association between herpes simplex virus type 2 and HIV over time (1984-2003).
Smit C, Pfrommer C, Mindel A, Taylor J, Spaargaren J, Berkhout B, Coutinho R, Dukers NH
Eur J Epidemiol. 2007;22(12):937-44. Epub 2007 Oct 10
Link to publication

Sexually transmitted infections, including HIV, in the Netherlands in 2006
MG van Veen, FDH Koedijk, IVF van der Broek, ELM Op de Coul, IM de Boer, AI van Sighem, MAB van der Sande National Institute for Public Health and the Environment and HIV Monitoring Foundation
RIVM report 210261003
Link to publication

Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, Viard JP, Reiss P, Francioli P, Lazzarin A, Machala L, Phillips AN, Lundgren JD; EuroSIDA study group and the Swiss HIV Cohort Study.
AIDS. 2007 Sep 12;21(14):1867-75.
Link to publication

Stichting Hiv Monitoring - de enige nationale cohortstudie in de wereld
Matthieu klein Tank
Soa AIDS magazine. 2007 Jaargang 4, nummer 4, Oktober. www.soaaidsmagazine.nl
Link to publication

The development of artificial neural networks to predict virological response to combination HIV therapy
Brendan Larder, Dechao Wang, Andrew Revell, Julio Montaner, Richard Harrigan, Frank De Wolf, Joep Lange, Scott Wegner, Lidia Ruiz, María Jésus Pérez-Elías, Sean Emery, Jose Gatell, Antonella D`Arminio Monforte, Carlo Torti, Maurizio Zazzi and Clifford Lan
Antiviral Therapy 2007; 12: 15-24
Link to publication
Pagina met onderzoek

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
Cleijsen RM, van de Ende ME, Kroon FP, Lunel FV, Koopmans PP, Gras L, de Wolf F, Burger DM.
J Antimicrob Chemother. 2007 Oct;60(4):897-900. Epub 2007 Aug 17.
Link to publication

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.
Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA); ART Cohort Collaboration, Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P
Clin Infect Dis. 2007 Dec 1;45(11):1518-21. Epub 2007 Oct 22.
Link to publication

Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis.
Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP.
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17441-6. Epub 2007 Oct 22.
Link to publication


Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use
Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.
AIDS. 2006 Oct 3;20(15):1941-1950.
Link to publication

Effects of Active Treatment Discontinuation in Patients With a CD4+ T-Cell Nadir Greater Than 350 Cells/mm3: 48-Week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
Pogany K, Vanvalkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, Kroon FP, Verbon A, Nievaard MF, Lange JM, Brinkman K.
J Acquir Immune Defic Syndr. 2006 Dec 21; [Epub ahead of print]
Link to publication
Research page

Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load.
Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L; CASCADE collaboration.
Antiviral Therapy 2006; 11: 173-17
Link to publication
Research page

HIV and Sexually Transmitted Infections in the Netherlands in 2005 RIVM report 441100024/2006
IM de Boer, ELM op de Coul, FDH Koedijk, MG van Veen, AI van Sighem, MJW van de Laar. RIVM, Center for Infectious Disease Control HIV Monitoring Foundation
Currently: ECDC Stockholm

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
M. Egger, B Ledergerber, J Lundgren, J Sterne, and A Phillips. M May, J Sterne, D Costagliola, M Egger, C Sabin, A Phillips, A Justice, F Dabis, J Gill, J Lundgren, R Hogg, F de Wolf, G Fätkenheuer, S Staszewski, and A d'Arminio Monforte.
Lancet Vol 368 August 5, 2006 451.
Link to publication
Research page

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD.
Arch Intern Med. 2006 Aug 14-28;166(15):1632-41.
Link to publication

Monitoring of Human Immunodeficiency Virus (HIV) infection in the Netherlands Report 2006
Gras L, van Sighem A, Smit C, Zaheri S, and de Wolf F, on behalf of the Netherlands collaborative HIV treatment centres. HIV Monitoring Foundation, Amsterdam, the Netherlands.
Link to publication

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collabor
Lancet. 2006 Mar 11;367(9513):817-24.
Link to publication
Erratum in: Lancet. 2006 Jun 10;367(9526):1902.

Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.
Antiretroviral Therapy Cohort Collaboration.
J Infect Dis. 2006 Sep 1;194(5):612-22. Epub 2006 Jul 31.
Link to publication

Schatting van het aantal volwassenen met HIV/aids in Nederland in 2005
E. Op de Coul, A. van Sighem, M. van de Laar
Infectieziekte bulletin. 2006 November 17(11):398-403
Link to publication

Semi-parametric accelerated failure time regression analysis with application to interval-censored HIV/AIDS data.
Xue H, Lam KF, Cowling BJ, de Wolf F.
Stat Med. 2006 Nov 30;25(22):3850-63
Link to publication
Research page

Soa en hiv Nederland in 2005
E.L.M. Op de Coul, I.M. de Boer, A.I. van Sighem
SOAAIDS Magazine on-line. 2006 December;3(5).
Link to publication

The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases.
Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC. Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College, London, UK.
Am J Epidemiol. 2006 Apr 1;163(7):676-83. Epub 2006 Feb 16
Link to publication
Research page

The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.
Hoefnagel JG, van der Lee MJ, Koopmans PP, Schuurman R, Jurriaans S, van Sighem AI, Gras L, de Wolf F, Galama JM, Burger DM.
AIDS. 2006 Apr 24;20(7):1069-1071
Link to publication
Research page

The HIV Monitoring Foundation
F. de Wolf
IATEC update. 2006 December
Link to publication

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.
Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD; D:A:D Study Group.
HIV Med. 2006 May;7(4):218-30
Link to publication
Research page